05:10 AM EDT, 07/14/2026 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured a contract worth 1.7 million kronor to provide its DiviTum TKa testing services to an unnamed pharmaceutical company. The Swedish biotechnology group said Tuesday that its services will be used for an up to four-year clinical breast cancer trial that will evaluate a CDK inhibitor with an endocrine treatment. The company noted that it will start testing in October at its CLIA-certified laboratory in California, US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.